Innate Pharma SA announced that lacutamab, an anti-KIR3DL2 antibody, demonstrated clinical responses in patients with mycosis fungoides (MF), in the ongoing Phase 2 TELLOMAK clinical trial. The results will be shared in an oral presentation at the EORTC CLTG1 Annual Meeting, taking place from 22-24 September 2022 in Madrid, Spain, presented by Pr. Martine Bagot, Head of the Dermatology Department, Saint Louis Hospital, Paris.

As of the March 4, 2022 data cutoff, patients in the KIR3DL2-expressing MF patients (cohort 2) received a median of 4 prior systemic therapies, and had a median follow-up of 12.2 months. In the KIR3DL2 non-expressing cohort (cohort 3), patients received a median of 4.5 prior systemic therapies and had a median follow-up of 13.8 months. Results showed that lacutamab produced a global objective response rate (ORR) of 28.6% (95% confidence interval [CI], 13.8-50.0) in the KIR3DL2-expressing MF patients (n=21), including 2 complete responses and 4 partial responses.

Results from the KIR3DL2 non-expressing cohort 3 are also presented. In line with previous observations, lacutamab demonstrated a favorable safety profile in MF also in the skin. Grade = 3 Treatment-related (TR) Treatment-Emergent Adverse events (TEAEs) were observed in 2/39 (5.1%) pts and 1/39 (2.6%) patients discontinued study drug due to adverse events.

Most common TR TEAEs were asthenia (N=5, 12.8%), arthralgia (N=4, 10.3%), and nausea (N=3, 7.7%).